Our results also suggest dual inhibition of PI3K and MEK pathways might not be particularly useful for EMT-related EGFR-TKI resistance in NSCLC, while this approach may be more effective against T790M-related acquired resistance to EGFR-TKI [54]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.